Daisy Lazarous, MD
Cardiovascular Disease · Washington, DCNPI 1952397382
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.3%), speaking fees and education — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by AstraZeneca at 46.6% of the total. Reporting peaked in 2021 at $3,855 and has fallen 61.3% since, to $1,493 in 2025.
Across 356 payments — averaging $35.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Novartis$760
- Pfizer$729
- Amgen$528
- Merck$512
- Boston Scientific$446
- plus $4K from 30 others
What the payments were for
- Speaking & faculty fees$5,40043%
- Travel & lodging$180%
- Food & beverage$7,14256%
- Education$1291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 32 | $5,919 |
| Novartis | 42 | $760 |
| Pfizer | 39 | $729 |
| Amgen | 23 | $528 |
| Merck | 30 | $512 |
| Boston Scientific | 14 | $446 |
| Bayer | 22 | $408 |
| E.r. Squibb & Sons, L.L.C. | 20 | $382 |
| Johnson & Johnson | 16 | $379 |
| Philips North America LLC | 19 | $350 |
| Amarin Pharma, Inc. | 15 | $254 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $240 |
| Boehringer Ingelheim | 9 | $210 |
| Alnylam Pharmaceuticals Inc. | 6 | $172 |
| Esperion Therapeutics, Inc. | 9 | $171 |
| Actelion Pharmaceuticals US, Inc. | 6 | $147 |
| Baxter Healthcare | 3 | $130 |
| Novo Nordisk | 6 | $127 |
| Preventice Services, LLC | 2 | $91 |
| Irhythm Technologies, Inc. | 3 | $85 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $80 |
| Lexicon Pharmaceuticals, Inc. | 3 | $66 |
| Regeneron Healthcare Solutions, Inc. | 3 | $64 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $61 |
| Atricure, Inc. | 2 | $61 |
| Astellas Pharma US Inc | 3 | $58 |
| Sanofi-aventis U.S. LLC | 2 | $45 |
| Scpharmaceuticals Inc. | 1 | $36 |
| Mannkind Corporation | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Braemar Manufacturing, LLC | 1 | $22 |
| Vital Connect, Inc | 1 | $21 |
| Kestra Medical Technology Services, Inc. | 1 | $20 |
| Medicomp Inc | 1 | $19 |
| Stryker | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$5,400
How this compares
$12,689 in reported general payments places this provider in the 85th percentile of 105 cardiovascular disease providers in District of Columbia.
See all cardiovascular disease providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 98 | $138,064 |
| EntrestoSacubitril/Valsartan | 67 | $121,414 |
| XareltoRivaroxaban | 20 | $29,362 |
| Repatha SureclickEvolocumab | 23 | $22,530 |
| Repatha SyringeEvolocumab | 12 | $10,465 |
| Ezetimibe | 193 | $8,810 |
| Atorvastatin Calcium | 603 | $8,045 |
| Rosuvastatin Calcium | 259 | $6,987 |
| Metoprolol Succinate | 350 | $5,749 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 156 | $5,321 |
| Valsartan | 101 | $4,232 |
| Amiodarone Hcl | 44 | $2,848 |
| Amlodipine Besylate | 174 | $1,469 |
| Losartan Potassium | 84 | $1,126 |
| Carvedilol | 110 | $1,115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $729 | $138,06498 claims |
| NovartisEntresto | $760 | $121,41467 claims |
| Johnson & JohnsonXarelto | $379 | $29,36220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 105 cardiovascular disease providers in District of Columbia.
Other cardiovascular disease in Washington
- Hayder HashimWashington$824K
- Joshua YamamotoWashington$376K
- Mardi Gomberg-MaitlandWashington$320K
- Jaffar KhanWashington$318K
- Isaac Opoku-AsareWashington$146K
- Judith HsiaWashington$65K
- Ana BaracWashington$34K
- Jonathan PlehnWashington$32K
- Andrew ChoiWashington$32K
- Felton AndersonWashington$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.